Breast Cancer Prevention Trial

Are you postmenopausal and taking hormone replacement therapy?

If you have any of the following, you may be eligible to participate in a breast cancer prevention clinical trial:

• Family history of breast cancer
• Prior breast biopsies
• Dense breast tissue on mammogram

If you answered yes to any of the above questions, you may be eligible to participate in a multi-institutional breast cancer prevention clinical trial currently available at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.

The trial allows you to continue your hormone replacement therapy, while taking letrozole, a medication being studied for prevention of breast cancer. Letrozole is currently approved by the FDA for treatment and prevention of recurrence of breast cancer.

A preliminary six-month study of letrozole in women without breast cancer taking hormone replacement therapy was associated with favorable changes in breast tissue without worsening quality of life.

This is a multi-institutional trial funded by the National Cancer Institute. Lisa Yee, MD, is The Ohio State University site principal investigator. 

For more information about this study or to see if you qualify, please contact Joanne Lester, PhD, CRNP, ANP-BC, AOCN at Joanne.Lester@osumc.edu

 

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu